DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20183481

Cross sectional study on different doses of acenocoumarol with INR in a tertiary care hospital

Keerthi E., Bhuvaneshwari S., Periyanarkunan Ramaiya Murugesan, Priyadharshini T., Sri Subiksha P.

Abstract


Background: It is of high value to be assess the relationship between doses of Acenocoumarol and the INR values to offer better patient care. Since Acenocoumarol is a commonly used drug with a narrow therapeutic range it is essential to monitor the variations encountered in response to it to avoid drastic complications and to provide better health care. Aim: The aim of this study is to compare the INR values with different doses of Acenocoumarol, to compare the association of dose of Acenocoumarol with their respective INR and to find out the occurrence of bleeding with different doses of Acenocoumarol.

Methods: The study was conducted in a Tertiary care hospital. 40 patients taking Acenocoumarol were recruited in the study. Relevant details like age, weight, dose of Acenocoumarol, INR and other concomitant drugs were obtained in a prospective manner. Correlation of dose of Acenocoumarol with respective INR was done by simple linear regression.

Results: The relationship between dose and INR was analyzed using Simple linear regression and the scatter plot revealed no significant correlation between the dose and INR values. There is a lot of inter-individual variability in the dose response and thereafter the INR values.

Conclusions: The dose of Acenocoumarol cannot predict INR values. Patient can ideally be started treatment on a low dose of Acenocoumarol and based on the INR values, dose can be titrated. There is a need for consideration of other factors which influence the dose and INR values.

 


Keywords


Acenocoumarol, Different doses, INR

Full Text:

PDF

References


Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants. Thrombosis and Haemostasis-Stuttgart. 1998 Dec 1;80:899-902.

Trailokya A, Hiremath JS, Sawhney J, Mishra YK, Kanhere V, Srinivasa R, et al. Acenocoumarol: A Review of Anticoagulant Efficacy and Safety. The J Asso of Physici of Indi. 2016 Feb;64(2):88-93.

Hirsch J, Dalen JE, Deykin D, Poller L. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1992 Oct 1;102(4):312S.

Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Therapeutics and clinical risk management. 2015;11:967.

Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. Clinical pharmacokinetics. 1996 Jun 1;30(6):416-44.

Becquemont L. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice. Eur J Clin Pharmacol. 2008 Oct 1;64(10):953.

Cesar JM, García-Avello A, Navarro JL, Herraez MV. Aging and oral anticoagulant therapy using acenocoumarol. Blood coagulation and fibrinolysis. 2004 Dec 1;15(8):673-6.

Van Schie RM, Wessels JA, le Cessie S, de Boer A, Schalekamp T, van der Meer FJ, et al. EU-PACT Study Group. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J. 2011 Jun 2;32(15):1909-17.

Borobia AM, Lubomirov R, Ramírez E, Lorenzo A, Campos A, Muñoz-Romo R, et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One. 2012 Jul 20;7(7):e41360.

Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, Mittal B. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One. 2012 May 22;7(5):e37844.